Roche
RO.SW
#44
Rank
โ‚ฌ294.37 B
Marketcap
369,99ย โ‚ฌ
Share price
3.02%
Change (1 day)
30.25%
Change (1 year)

P/E ratio for Roche (RO.SW)

P/E ratio at the end of 2025: 19.9

According to Roche's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.4604. At the end of 2025 the company had a P/E ratio of 19.9.

P/E ratio history for Roche from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202519.9-28.11%
202427.660.17%
202317.2-25.96%
202223.3-4.18%
202124.343.67%
202016.9-10.72%
201919.01.8%
201818.6-16.13%
201722.213.42%
201619.6-15.17%
201523.112.39%
201420.548.81%
201313.812.51%
201212.312.65%
201110.913.12%
20109.62-34.15%
200914.626.54%
200811.5-18.81%
200714.2-33.93%
200621.5-19.79%
200526.892.13%
200414.0-62.1%
200336.9-300.94%
2002-18.3-218.88%
200115.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
27.4 33.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.8 6.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
18.9-7.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
25.1 22.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
24.0 17.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
16.3-20.57%๐Ÿ‡ซ๐Ÿ‡ท France
Becton Dickinson
BDX
26.4 28.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
33.6 64.32%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.4-34.52%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.